A first-in-human study of KK8123 in adults with X-linked hypophosphatemia

• Research type

  Research Study

• Full title

  A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients with X-linked Hypophosphatemia.

• IRAS ID

  1009715

• Contact name

  Rowitha Reisinger

• Contact email

  roswitha.reisinger@kyowakirin.com

• Sponsor organisation

  Kyowa Kirin, Inc.

• Eudract number

  2023-509390-23

• Research summary

  The purpose of this study is to test the safety and effectiveness of an investigational drug called KK8123. KK8123 is given as a subcutaneous (under the skin) injection and is expected to stop the action of fibroblast growth factor 23 (FGF23) and thereby normalise blood phosphorus levels, which may help improve XLH symptoms

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  24/SC/0282

• Date of REC Opinion

  12 Nov 2024

• REC opinion

  Further Information Favourable Opinion